HR18034

· Shanghai Hengrui Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for HR18034, covering 2023-03-15 to 2024-10-30. Get the full timeline:

Most recent: Clinical Trial Update: Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management in TKA [Phase 2]